A bladder cancer prognostic marker, a prognostic evaluation system and its application

By detecting the expression levels of OTUD6A and CDC6 in bladder cancer, and using immunohistochemistry to evaluate the malignancy of bladder cancer, the problem that the existing technology cannot effectively evaluate the prognosis of bladder cancer is solved, the survival rate of patients is improved and clinical treatment is provided. New ideas.

CN114660291BActive Publication Date: 2024-11-12SHANDONG UNIV QILU HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210444452.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-26
Publication Date
2024-11-12
Estimated Expiration
2042-04-26

AI Technical Summary

Technical Problem

There are currently a lack of clear indicators for evaluating the prognosis of patients with bladder cancer, and the prior art cannot effectively judge the degree of malignancy of bladder cancer and the survival rate of patients.

Method used

Through the study, it was found that the expression of OTUD6A and CDC6 in bladder cancer significantly increased, and the expression levels of OTUD6A and CDC6 were evaluated using immunohistochemical detection methods to judge the degree of malignancy of bladder cancer and the prognosis of patients.

Benefits of technology

It has achieved the accuracy of prognosis evaluation of bladder cancer patients, improved the survival rate of bladder cancer patients, and provided new ideas for the clinical treatment of bladder cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114660291B_ABST
    Figure CN114660291B_ABST
Patent Text Reader

Abstract

The present invention provides a bladder cancer prognostic marker, a prognostic evaluation system and an application thereof, and belongs to the technical field of tumor prognosis evaluation. The present invention finds through research that the expression of OTUD6A and CDC6 is significantly increased in bladder cancer, and at the same time, the research shows that the expression of OTUD6A and CDC6 is closely related to the overall survival rate of bladder cancer patients. Therefore, the purpose of judging the malignancy of bladder cancer and the prognosis of patients can be achieved by detecting the expression of OTUD6A and CDC6, thereby helping to improve the survival rate of bladder cancer patients and providing new ideas for clinical precision treatment decisions of bladder cancer, so it has good clinical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of tumor prognosis evaluation, and in particular relates to a bladder cancer prognosis marker, a prognosis evaluation system and applications thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Urothelial carcinoma is one of the common clinical diseases in urology, including bladder cancer, renal pelvic cancer, and ureteral cancer. Bladder cancer accounts for more than 90% of all urothelial carcinomas and is often found in men, with a male-to-female ratio of about 4:1. Bladder cancer has a high risk of recurrence and death, and the 5-year survival rate of muscle-invasive bladder cancer is less than 50%. According to the latest global cancer statistics in 2022, bladder cancer ranks fourth in incidence and ninth in mortality among men. However, in addition to the currently known tumor grading, staging, lymph node metastasis, and ki-67 staining, which can judge the malignancy of the tumor and the prognosis of the patient, there are currently no clear indicators to evaluate the prognosis of the patient.

[0004] Immunohistochemistry (Immunohistochemistry, IHC) detection, is to utilize the principle of antigen-antibody specific binding, through chemical reaction, the color developer (fluorescein, enzyme, metal ion, isotope) of the labeled antibody is developed to determine the antigen (peptide and protein) in the tissue or cell, and to study its location, qualitative and relative quantitative. Because immunohistochemistry has the characteristics of strong specificity, high sensitivity, accurate positioning, and can organically combine morphological research with functional research, it has been widely used in many fields of biological and medical research. In pathological research, the role and significance of immunohistochemistry are obviously more important. However, the inventors have found that there are few reports on methods for evaluating the malignancy and prognosis of bladder cancer using immunohistochemical detection means. Summary of the invention

[0005] Based on the above-mentioned deficiencies of the prior art, the present invention provides a bladder cancer prognosis marker, a prognosis evaluation system and its application. The present invention has found through research that the expression of OTUD6A and CDC6 is significantly increased in bladder cancer, and studies have shown that the expression of OTUD6A and CDC6 is closely related to the overall survival rate of bladder cancer patients. Therefore, the purpose of judging the malignancy of bladder cancer and the prognosis of patients can be achieved by detecting the expression of OTUD6A and CDC6. Based on the above research results, the present invention is completed.

[0006] The technical solution of the present invention is as follows:

[0007] In a first aspect of the present invention, a bladder cancer prognosis marker is provided, wherein the bladder cancer prognosis marker comprises OTUD6A and CDC6.

[0008] The second aspect of the present invention provides the use of a substance for detecting the above-mentioned prognostic marker in the preparation of a bladder cancer-related detection product.

[0009] Among them, the bladder cancer related detection products include a bladder cancer immunohistochemistry detection kit, which can be used to determine the malignancy of bladder cancer and the prognosis of patients.

[0010] The third aspect of the present invention provides a product, which comprises a substance for detecting the above-mentioned prognostic marker, and the product is used for prognostic assessment of bladder cancer.

[0011] The fourth aspect of the present invention provides the use of the above-mentioned prognostic markers and products in the preparation of a bladder cancer prognosis assessment system.

[0012] A fifth aspect of the present invention provides a bladder cancer prognosis assessment system, the system comprising: an analysis unit and an assessment unit;

[0013] Wherein, the analysis unit is used to obtain the results of OTUD6A and CDC6 of the subject;

[0014] The evaluation unit assigns corresponding evaluation scores to obtain a total score based on the results of OTUD6A and CDC6, and outputs the corresponding prognostic status of the subject;

[0015] Beneficial technical effects of one or more of the above technical solutions:

[0016] The above technical solution uses immunohistochemical staining of CDC6 and OTUD6A proteins in patient tissue specimens to detect their expression levels, judge the prognosis based on the expression levels of the two, and evaluate the malignancy of the tumor; at the same time, it can also evaluate the patient's prognosis, thereby helping to improve the survival rate of bladder cancer patients and provide new ideas for clinical precision treatment decisions for bladder cancer. Therefore, it has good clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0018] Figure 1 The expression levels of OTUD6A and CDC6 proteins in 20 bladder cancer and adjacent tissue specimens in the embodiment of the present invention (top) and the relative expression levels of OTUD6A protein (lower left) and CDC6 protein (lower right) in tumor tissue and adjacent tissue.

[0019] Figure 2 This is the correlation analysis of OTUD6A and CDC6 protein expression in bladder tumor tissue in the embodiment of the present invention.

[0020] Figure 3 : is the mRNA expression level of OTUD6A (left) and CDC6 (right) in the tumor and adjacent tissue specimens in the embodiment of the present invention.

[0021] Figure 4 CDC6 and OTUD6A expression in normal urothelial and bladder cancer cell lines (left), and protein expression correlation analysis (right) in the examples of the present invention.

[0022] Figure 5 This is an immunohistochemical staining diagram of OTUD6A and CDC6 in the bladder cancer tissue chip in an embodiment of the present invention.

[0023] Figure 6 ] is the survival curve of patients with high and low expression of OTUD6A in the embodiment of the present invention.

[0024] Figure 7 2 are the survival curves of patients with high and low expression of CDC6 in the embodiment of the present invention.

[0025] Figure 8 This is a survival curve for judging the prognosis of a patient by combining the expression of OTUD6A with CDC6 in an embodiment of the present invention. DETAILED DESCRIPTION

[0026] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0027] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments of the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0028] In a specific embodiment of the present invention, a bladder cancer prognosis marker is provided, and the bladder cancer prognosis marker includes OTUD6A and / or CDC6.

[0029] Specifically, the present invention found that the expression levels of OTUD6A and CDC6 in bladder cancer were significantly higher than those in normal bladder epithelium, and the expression levels of OTUD6A and CDC6 proteins were significantly positively correlated; and the overall survival rate of OTUD6A and CDC6 were analyzed respectively using the patient prognosis information in the bladder cancer tissue chip, and the results showed that the overall survival rate of bladder cancer patients with low OTUD6A expression was significantly higher than that of the high expression group, and the overall survival rate of bladder cancer patients with low CDC6 expression was also significantly higher than that of the high expression group. OTUD6A and CDC6 proteins were used together to predict the survival of bladder cancer patients. The survival analysis results showed that the overall survival rate of patients with high expression of OTUD6A and CDC6 was the lowest, and the overall survival rate of patients with low expression of OTUD6A and CDC6 was the highest. The overall survival rate of patients with low expression of OTUD6A and high expression of CDC6 was lower than that of patients with high expression of OTUD6A and low expression of CDC6.

[0030] In another specific embodiment of the present invention, there is provided use of a substance for detecting the above-mentioned prognostic marker in the preparation of a bladder cancer-related detection product.

[0031] Among them, the bladder cancer related detection products include a bladder cancer immunohistochemistry detection kit, which can be used to determine the malignancy of bladder cancer and the prognosis of patients.

[0032] In another specific embodiment of the present invention, a product is provided, wherein the product comprises a substance for detecting the above-mentioned prognostic marker, and the product is used for prognostic assessment of bladder cancer.

[0033] The products include but are not limited to preparations or kits for detecting the expression of OTUD6A and / or CDC6 in a sample to be tested.

[0034] The sample to be tested may be a human sample, and more specifically, the sample to be tested includes a bladder (cancer) tissue of a subject.

[0035] In another embodiment of the present invention, the product can be an immunohistochemical detection kit. Therefore, the kit can include a primary antibody, a secondary antibody, an endogenous hydrogen peroxide scavenger, a color developing reagent (such as DAB solution) that reacts with horseradish peroxidase and develops color, a reagent that specifically stains cell nuclei in tissues (such as hematoxylin), etc.

[0036] The primary antibody is specifically an OTUD6A and CDC6 specific antibody prepared against human OTUD6A and CDC6 antigens, such as a rabbit anti-human OTUD6A polyclonal antibody, a rabbit anti-human CDC6 specific antibody, etc., which is not specifically limited here.

[0037] Correspondingly, the secondary antibody only needs to match the species, class or subclass of the primary antibody. For example, when the primary antibody is a rabbit anti-human OTUD6A or CDC6 polyclonal antibody, the secondary antibody can be a goat anti-rabbit IgG.

[0038] In another specific embodiment of the present invention, there is provided the use of the above-mentioned prognostic markers and products in the preparation of a bladder cancer prognosis assessment system.

[0039] The bladder cancer prognosis evaluation system can be used to evaluate the malignancy and survival rate of bladder cancer in a subject.

[0040] In another specific embodiment of the present invention, a bladder cancer prognosis assessment system is provided, the system comprising: an analysis unit and an assessment unit;

[0041] Wherein, the analysis unit is used to obtain the results of OTUD6A and / or CDC6 of the subject;

[0042] The evaluation unit assigns corresponding evaluation scores to obtain a total score based on the results of OTUD6A and / or CDC6, and outputs the corresponding prognostic status of the subject;

[0043] More specifically, the results of OTUD6A and / or CDC6 of the subject are the staining intensity obtained after immunohistochemical staining and the area of ​​positive cells in the whole tissue.

[0044] The specific evaluation process of the evaluation unit includes: dividing the staining intensity into negative 0 points, weak 1 point, medium 2 points, and strong positive 3 points; dividing the area of ​​positive cells in the entire tissue into less than 5% 0 points, 5%-25% 1 point, 26%-50% 2 points, 51%-75% 3 points, and greater than 75% 4 points; multiplying the two scores; 0-7 points are judged as low expression, and 8-12 points are judged as high expression.

[0045] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0046] Example

[0047] The method for evaluating the malignancy of bladder cancer and the prognosis of patients using an immunohistochemical detection kit includes the following steps:

[0048] (1) Bladder cancer tissue removed from a patient is embedded and sliced ​​to obtain paraffin sections.

[0049] (2) Place the paraffin sections in a 65°C oven for 30 minutes to 1 hour until the remaining wax on the tissue is completely removed.

[0050] (3) Carry out dewaxing treatment according to the table below.

[0051]

[0052]

[0053] (4) Dilute 50× antigen repair solution to 1× with triple distilled water, place in a microwave oven on high heat for 5 minutes, place the slide in the boiling antigen repair solution, and heat on low heat for 17 minutes. Allow the antigen repair solution to cool naturally at room temperature.

[0054] (5) Wash the slides three times with PBS, 3 minutes each time.

[0055] (6) Circle the tissue with a tissue pen, add endogenous hydrogen peroxide scavenger in a dark place, let stand at room temperature for 20 minutes, and then wash the slide three times with PBS, each time for 3 minutes.

[0056] (7) Add 5% BSA solution to the tissue and let it stand at room temperature for 1 hour for blocking.

[0057] (8) Dilute CDC6 and OTUD6A primary antibodies (rabbit anti-human OTUD6A polyclonal antibody (Proteintech, Catalog No. 24486-1-AP); recombinant rabbit anti-human CDC6 antibody (Abcam, Catalog No. ab109315) with PBS.

[0058] ), pour off the blocking solution and add the primary antibody so that the primary antibody completely covers the tissue, and incubate at 4°C overnight.

[0059] (9) The next day, take out the slides and place them at room temperature to warm up for 1 hour.

[0060] (10) After removing the primary antibody, wash the slides three times with PBS, each time for 3 minutes.

[0061] (11) Add secondary antibody, which is goat anti-rabbit IgG, Jackson ImmunoResearch, catalog number 711-035-152, and incubate at room temperature for 1 hour.

[0062] (12) Wash the slides three times with PBS, 3 minutes each time.

[0063] (13) Mix 10 μL of 20×DAB solution with 190 μL of DAB substrate solution (scale up or down in proportion to the size and quantity of the tissue on the slide).

[0064] (14) Add 1×DAB solution to the tissue and observe it under a microscope. When the staining is moderate, place it in PBS.

[0065] (15) Add hematoxylin to the tissue for 30 seconds and rinse in running water for 5 minutes.

[0066] (16) Carry out dehydration treatment according to the table below.

[0067]

[0068] (17) Add a drop of neutral gum to the glass slide for sealing.

[0069] (18) The next day, the cells were observed and images were recorded under an upright microscope.

[0070] (19) Staining scores were based on the following criteria: Staining intensity was divided into negative (0), weak (1), moderate (2), and strongly positive (3); the area of ​​positive cells in the entire tissue was divided into less than 5% (0), 5%-25% (1), 26%-50% (2), 51%-75% (3). Greater than 75% (4). The two scores were multiplied. 0-7 was considered low expression, and 8-12 was considered high expression.

[0071] Western blot was performed to detect the expression of OTUD6A and CDC6 in 20 pairs of bladder cancer and adjacent adjacent tissues. Figure 1 As shown in Figure 2, OTUD6A and CDC6 proteins were upregulated in bladder cancer tissues compared with adjacent adjacent tissues. Figure 2 As shown in the figure, the expression of OTUD6A and CDC6 proteins was significantly positively correlated. RT-qPCR results showed that the mRNA expression of OTUD6A and CDC6 in bladder cancer tissues was higher than that in adjacent tissues ( Figure 3 ). The results of detecting CDC6 and OTUD6A proteins in different bladder cancer cell lines and urothelial cell lines are as follows Figure 4 As shown in Figure 2, OTUD6A and CDC6 protein expressions were significantly positively correlated (r 2 =0.7302, P = 0.0302). Immunohistochemical staining of OTUD6A and CDC6 was performed on a chip containing 68 bladder cancer and 40 normal bladder epithelial tissues, and immunohistochemical scores were performed according to staining intensity and area. The results showed that the expression levels of OTUD6A and CDC6 in cancer were significantly higher than those in normal bladder epithelium, and the expression levels of OTUD6A and CDC6 proteins had a significant positive correlation (r 2 =0.2905,P<0.0001, Figure 5 ). The above results indicate that OTUD6A and CDC6 protein expressions are positively correlated in bladder cancer.

[0072] The overall survival rate of OTUD6A and CDC6 was analyzed by Kaplan-Meier plot using the prognostic information of patients in bladder cancer tissue microarray. The results showed that the overall survival rate of bladder cancer patients with low OTUD6A expression was significantly higher than that of the high expression group ( Figure 6 ), the overall survival rate of bladder cancer patients with low CDC6 expression was also significantly higher than that of the high expression group ( Figure 7 ). OTUD6A and CDC6 proteins were used together to predict the survival of bladder cancer patients. The results of survival analysis showed that the patients with high expression of both OTUD6A and CDC6 had the lowest overall survival rate, while the patients with low expression of both OTUD6A and CDC6 had the highest overall survival rate. The overall survival rate of patients with low expression of OTUD6A and high expression of CDC6 was lower than that of patients with high expression of OTUD6A and low expression of CDC6 (P=0.0307, Figure 8 ), suggesting that OTUD6A combined with CDC6 expression has the value of guiding the prognosis of bladder cancer patients.

[0073] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to perform equivalent replacements on parts thereof. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention. Although the above describes the specific implementation methods of the present invention, it is not intended to limit the protection scope of the present invention. Those skilled in the art should understand that, based on the technical solution of the present invention, various modifications or deformations that can be made by those skilled in the art without creative labor are still within the protection scope of the present invention.

Claims

1. Use of a substance for detecting OTUD6A and CDC6 in the preparation of a bladder cancer-related detection product, wherein the bladder cancer-related detection product comprises a bladder cancer immunohistochemistry detection kit, which is used to determine the prognosis of bladder cancer patients.

2. Application of substances for detecting OTUD6A and CDC6 in the preparation of bladder cancer prognosis evaluation system.

3. A bladder cancer prognosis assessment system, characterized in that: The system comprises: an analysis unit and an evaluation unit; Wherein, the analysis unit is used to obtain the results of the prognostic markers of the subject; the prognostic markers are OTUD6A and CDC6; The evaluation unit assigns corresponding evaluation scores to obtain a total score based on the results of obtaining the prognostic markers, and outputs the corresponding prognostic status of the subject.

4. The system according to claim 3, characterized in that: The results of prognostic markers were obtained by immunohistochemical staining, including the staining intensity and the area of ​​positive cells in the whole tissue.

5. The system according to claim 3, characterized in that: The specific evaluation process of the evaluation unit includes: dividing the staining intensity into negative 0 points, weak 1 point, medium 2 points, and strong positive 3 points; dividing the area of ​​positive cells in the entire tissue into less than 5% 0 points, 5%-25% 1 point, 26%-50% 2 points, 51%-75% 3 points, and greater than 75% 4 points; multiplying the two scores; 0-7 points are judged as low expression, and 8-12 points are judged as high expression.